Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
32.9 USD -3.06% Intraday chart for Neurogene Inc. -2.58% +69.76%
May. 07 Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting CI
Apr. 29 Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target MT

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 248.5 423.3 - -
Enterprise Value (EV) 1 51.47 96.18 -77.82 423.3
P/E ratio -2.49 x -8.52 x -9.08 x -7.04 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF -0.99 x -1.39 x 1.02 x -5.1 x
FCF Yield -101% -71.7% 97.7% -19.6%
Price to Book - - - -
Nbr of stocks (in thousands) 12,824 12,866 - -
Reference price 2 19.38 32.90 32.90 32.90
Announcement Date 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 - -55.58 -65.24 -78.36 -89
Operating Margin - - - - -
Earnings before Tax (EBT) 1 - -36.32 -59.24 -75.62 -88.86
Net income 1 -55.19 -36.32 -66.08 -74.56 -86.35
Net margin - - - - -
EPS 2 -10.58 -7.798 -3.860 -3.624 -4.670
Free Cash Flow 1 - -51.74 -69 -76 -83
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 11/8/23 3/18/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -14.73 -15.32 -15.95 -16.64 -17.37
Operating Margin - - - - -
Earnings before Tax (EBT) 1 2.383 -13.81 -14.42 -15.12 -15.89
Net income 1 2.383 -16.77 -15.65 -16.53 -17.27
Net margin - - - - -
EPS 2 - -1.034 -0.9775 -1.020 -0.9500
Dividend per Share - - - - -
Announcement Date 3/18/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - 197 327 501 -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -51.7 -69 -76 -83
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - 0.32 1.5 1.1 -
Capex / Sales - - - - -
Announcement Date 11/8/23 3/18/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
32.9 USD
Average target price
51.5 USD
Spread / Average Target
+56.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NEUROGENE INC. Stock Neurogene Inc.
+69.76% 437M
MODERNA, INC. Stock Moderna, Inc.
+22.56% 46.4B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.51% 41.75B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.13% 26.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.44% 19.52B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 12.43B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.14% 12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 12.13B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. Financials Neurogene Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW